Compass Pathways Secures FDA Trial Protocol Clearance for Psilocybin Therapy
COMP•COMP•COMP•COMP•Compass Pathways secured FDA clearance on its pivotal trial protocol for its psilocybin-based treatment-resistant depression therapy, marking its second regulatory milestone this year. The company refined its Phase III design with updated primary endpoints and enhanced safety monitoring to strengthen its approval case.
Compass Pathways obtained formal FDA clearance on its Phase III trial protocol for its lead psilocybin therapy targeting treatment-resistant depression. The agency’s agreement on primary endpoints and safety monitoring plans reduces regulatory risk and solidifies the design ahead of full study launch.
This clearance represents a second major regulatory achievement for Compass Pathways this year, enhancing confidence among investors and potential partners. With protocol details settled, the company can focus on site activation, patient enrollment and preparations for its pivotal efficacy study.
